John R Wunderlich
Overview
Explore the profile of John R Wunderlich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
13462
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Stevanovic S, Draper L, Langhan M, Campbell T, Kwong M, Wunderlich J, et al.
J Clin Oncol
. 2015 Apr;
33(14):1543-50.
PMID: 25823737
Purpose: Metastatic cervical cancer is a prototypical chemotherapy-refractory epithelial malignancy for which better treatments are needed. Adoptive T-cell therapy (ACT) is emerging as a promising cancer treatment, but its study...
12.
Robbins P, Kassim S, Tran T, Crystal J, Morgan R, Feldman S, et al.
Clin Cancer Res
. 2014 Dec;
21(5):1019-27.
PMID: 25538264
Purpose: Although adoptive cell therapy can be highly effective for the treatment of patients with melanoma, the application of this approach to the treatment of other solid tumors has been...
13.
Chandran S, Paria B, Srivastava A, Rothermel L, Stephens D, Dudley M, et al.
Clin Cancer Res
. 2014 Nov;
21(3):534-43.
PMID: 25424856
Purpose: Adoptive transfer of autologous tumor infiltrating lymphocytes (TIL) can mediate durable cancer regression in selected patients with metastatic melanoma. However, the tumor antigens associated with these favorable responses remain...
14.
Tran E, Turcotte S, Gros A, Robbins P, Lu Y, Dudley M, et al.
Science
. 2014 May;
344(6184):641-5.
PMID: 24812403
Limited evidence exists that humans mount a mutation-specific T cell response to epithelial cancers. We used a whole-exomic-sequencing-based approach to demonstrate that tumor-infiltrating lymphocytes (TIL) from a patient with metastatic...
15.
Gros A, Robbins P, Yao X, Li Y, Turcotte S, Tran E, et al.
J Clin Invest
. 2014 Mar;
124(5):2246-59.
PMID: 24667641
Adoptive transfer of tumor-infiltrating lymphocytes (TILs) can mediate regression of metastatic melanoma; however, TILs are a heterogeneous population, and there are no effective markers to specifically identify and select the...
16.
Bartlett E, Fetsch P, Filie A, Abati A, Steinberg S, Wunderlich J, et al.
Clin Cancer Res
. 2014 Mar;
20(10):2607-2616.
PMID: 24647571
Purpose: Metastasis heterogeneity presents a significant obstacle to the development of targeted cancer therapeutics. In this study, we sought to establish from a large series of human melanoma metastases whether...
17.
Pos Z, Spivey T, Liu H, Sommariva M, Chen J, Wunderlich J, et al.
J Invest Dermatol
. 2013 Nov;
134(5):1389-1396.
PMID: 24270663
Recurrent metastatic melanoma provides a unique opportunity to analyze disease evolution in metastatic cancer. Here, we followed up eight patients with an unusually prolonged history of metastatic melanoma, who developed...
18.
Turcotte S, Gros A, Tran E, Lee C, Wunderlich J, Robbins P, et al.
Clin Cancer Res
. 2013 Nov;
20(2):331-43.
PMID: 24218514
Purpose: To evaluate whether patients with metastatic gastrointestinal adenocarcinomas refractory to chemotherapy harbor tumor-reactive cytotoxic T cells. Experimental Design: Expansion of CD8(+) tumor-infiltrating lymphocytes (TIL) and cancer cell lines was...
19.
Beard R, Abate-Daga D, Rosati S, Zheng Z, Wunderlich J, Rosenberg S, et al.
Clin Cancer Res
. 2013 Sep;
19(18):4941-50.
PMID: 24021875
Purpose: The success of immunotherapy for the treatment of metastatic cancer is contingent on the identification of appropriate target antigens. Potential targets must be expressed on tumors but show restricted...
20.
Turcotte S, Gros A, Hogan K, Tran E, Hinrichs C, Wunderlich J, et al.
J Immunol
. 2013 Aug;
191(5):2217-25.
PMID: 23904171
Adoptive cell transfer of tumor-infiltrating lymphocytes (TILs) can mediate cancer regression in patients with metastatic melanoma, but whether this approach can be applied to common epithelial malignancies remains unclear. In...